title: Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai Conference recommendations.
abstract: Schizophrenia is associated with several chronic medical illnesses and a reduced life expectancy. This paper summarizes findings and recommendations from "The Mount Sinai Conference," held at the Mount Sinai School of Medicine in New York on October 17-18, 2002, and discusses the implications for improving medical monitoring of patients with schizophrenia who are managed in outpatient settings from the initiation of treatment. The Mount Sinai Conference involved a diverse panel of experts, including specialists on schizophrenia, obesity, diabetes, cardiology, endocrinology, and ophthalmology. Consensus recommendations included baseline measurement and regular monitoring of body mass index, blood glucose, lipid profiles, signs of prolactin elevation or sexual dysfunction, and movement disorders. Information from such measurements should be considered when selecting or switching antipsychotic agents and should trigger an evaluation of medication when abnormalities are detected.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine, Connecticut DMHAS Research Division, Hartford 06134, USA. Nancy.covell@po.state.ct.us
authors.forename: Nancy H
authors.initials: NH
authors.lastname: Covell
authors.forename: Carlos T
authors.initials: CT
authors.lastname: Jackson
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Weissman
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000517:prevention & control; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D002386:Cataract / Q000139:chemically induced / Q000517:prevention & control; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000517:prevention & control; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control; D009205:Myocarditis / Q000139:chemically induced / Q000517:prevention & control; D009765:Obesity / Q000150:complications / Q000517:prevention & control; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000517:prevention & control; D015430:Weight Gain / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents